logo
  

AK Steel Q2 Loss Widens; But Sees Improved Results In Q3 - Quick Facts

AK Steel Holding Corp. (AKS) reported second-quarter net loss attributable to the company of $64.0 million or $0.36 per share, wider than loss of $17.1 million or $0.13 per share in the comparable quarter last year.

On average, 17 analysts polled by Thomson Reuters expected the company to report loss of $0.37 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter were $1.69 billion on shipments of 1,811,700 tons, compared with net sales of $1.53 billion on shipments of 1,397,500 tons for the year-ago quarter. Analysts expected quarterly sales of $1.70 billion.

The year-on-year increase in shipments due principally to the addition of shipments from Dearborn Works, acquired in September of 2014, and continued strong shipments of carbon and stainless products to the automotive market.

AK Steel said it will provide detailed guidance for its third-quarter financial results in September. However, for a variety of reasons, the company expects to generate improved results for the third quarter and for the second-half of 2015 as compared to the second quarter and first-half of 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT